News

Argenica Therapeutics says ARG-007 reduced damage to brain cells in preclinical study February 4, 2025

Argenica Therapeutics (ASX:AGN) has announced results from a more extensive preclinical study assessing the efficacy of ARG-007 in a rat model of moderate traumatic brain injury.

Emyria announces promising follow-up clinical trial results for PTSD program February 4, 2025

Dr Jon Laugharne, Emyria’s lead psychiatrist, said, “It’s encouraging to see that patients continue to experience meaningful improvements in PTSD symptoms and overall well-being even months after completing treatment."

AusBiotech and MTPConnect use joint Pre-Budget submission to promote investment in strategic initiatives February 4, 2025

In a pre-budget submission, AusBiotech and MTPConnect have called for new investment in strategic initiatives to boost Australia’s life sciences sector.

AdvanCell successfully completes an oversubscribed Series C Financing February 4, 2025

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 million Series C financing.

Noxopharm says SOF-SKN passes required in vitro safety tests February 4, 2025

Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial.

Anatara announces Australian patent granted for GaRP candidate January 30, 2025

Anatara Lifesciences (ASX:ANR) has reported that it has received certification of the grant of a standard patent on 23 January for the GaRP product under the invention title of 'Gastrointestinal Health Composition'.

Biome reports positive results on clinical development of BMB18 January 30, 2025

Microbiome health company Biome Australia (ASX:BIO) has updated investors on the strain development program.

Alterity Therapeutics announces positive trial results in Multiple System Atrophy January 30, 2025

Alterity Therapeutics (ASX:ATH) has announced positive topline results from the ATH434-201 randomised, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy.

New link revealed between hypertension and the gut January 30, 2025

According to Monash University researchers, the gut and two-cell regulators may pave the way to better high-blood-pressure drugs.

AusBiotech congratulates members recognised in Australia Day Honours January 30, 2025

AusBiotech has celebrated the achievements of members recognised in this year's Australia Day Honours List.

TGA approves CSL's locally discovered and developed biologic January 28, 2025

“I realised we had something special when our lead scientist on this programme came into my office and showed me some data related to the screening they'd been doing," said Dr Andrew Nash, CSL’s chief scientific officer.

IDT updates investors, expecting a significant spike in revenue January 28, 2025

Pharmaceutical manufacturer IDT Australia (ASX:IDT) has updated investors, reporting a significant rise in revenue for the final three months of the calendar year 2024.

Most Read

AdvanCell successfully completes an oversubscribed Series C Financing

AusBiotech and MTPConnect use joint Pre-Budget submission to promote investment in strategic initiatives

Emyria announces promising follow-up clinical trial results for PTSD program

Argenica Therapeutics says ARG-007 reduced damage to brain cells in preclinical study

Noxopharm says SOF-SKN passes required in vitro safety tests

New Stories

Argenica Therapeutics says ARG-007 reduced damage to brain cells in preclinical study

Emyria announces promising follow-up clinical trial results for PTSD program

AusBiotech and MTPConnect use joint Pre-Budget submission to promote investment in strategic initiatives

AdvanCell successfully completes an oversubscribed Series C Financing

Noxopharm says SOF-SKN passes required in vitro safety tests

Anatara announces Australian patent granted for GaRP candidate

Biome reports positive results on clinical development of BMB18

Sign In

Most Read

AdvanCell successfully completes an oversubscribed Series C Financing

AusBiotech and MTPConnect use joint Pre-Budget submission to promote investment in strategic initiatives

Emyria announces promising follow-up clinical trial results for PTSD program

Argenica Therapeutics says ARG-007 reduced damage to brain cells in preclinical study

Noxopharm says SOF-SKN passes required in vitro safety tests

Follow Us

New Stories

Argenica Therapeutics says ARG-007 reduced damage to brain cells in preclinical study

Emyria announces promising follow-up clinical trial results for PTSD program

AusBiotech and MTPConnect use joint Pre-Budget submission to promote investment in strategic initiatives

AdvanCell successfully completes an oversubscribed Series C Financing

Noxopharm says SOF-SKN passes required in vitro safety tests

Anatara announces Australian patent granted for GaRP candidate

Biome reports positive results on clinical development of BMB18